• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of February 3

Article

The Center for Biosimilars® recaps the top stories for the week of February 3, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 3, 2020.

Number 5: The European Medicines Agency’s Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer's Ruxience, a rituximab biosimilar.

Number 4: The FDA announces 6 final guidance documents on gene therapy manufacturing and clinical development of products, as well as a draft guidance regarding gene therapies and orphan drugs.

Number 3: In an effort to speed more generic drug approvals, the FDA says it is changing how it assigns priority review status to abbreviated new drug applications.

Number 2: Celltrion recalls its employees from China’s Wuhan province until the coronavirus outbreak is brought under control.

Number 1: Merck says it is spinning off its biosimilars business to focus on its oncology drug Keytruda.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of June 10, 2024.
Lakesha Farmer, PharmD
The Top 5 Biosimilar Articles of the Week.
Here are the top 5 biosimilar articles for the week of May 27, 2024.
Lakesha Farmer from Cencora
Here are the top 5 biosimilar articles for the week of May 20, 2024.
Here are the top 5 biosimilar articles for the week of May 13, 2024.
Jeffrey Casberg, RPh, MS.
Related Content
© 2024 MJH Life Sciences

All rights reserved.